AXQ Capital LP Takes $39,000 Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

AXQ Capital LP acquired a new position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 22,432 shares of the company’s stock, valued at approximately $39,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Cibc World Markets Corp purchased a new position in shares of Taysha Gene Therapies during the 4th quarter worth $28,000. E Fund Management Co. Ltd. bought a new position in Taysha Gene Therapies in the 4th quarter worth $31,000. Intech Investment Management LLC purchased a new position in Taysha Gene Therapies during the third quarter valued at $85,000. Commonwealth Equity Services LLC lifted its position in Taysha Gene Therapies by 110.4% during the fourth quarter. Commonwealth Equity Services LLC now owns 59,069 shares of the company’s stock valued at $102,000 after purchasing an additional 31,000 shares in the last quarter. Finally, MetLife Investment Management LLC grew its holdings in Taysha Gene Therapies by 81.9% during the third quarter. MetLife Investment Management LLC now owns 76,037 shares of the company’s stock valued at $153,000 after purchasing an additional 34,243 shares during the period. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Price Performance

Shares of NASDAQ:TSHA opened at $1.66 on Tuesday. The firm has a market cap of $340.30 million, a price-to-earnings ratio of 2.63 and a beta of 0.91. The firm has a fifty day moving average price of $1.63 and a 200 day moving average price of $1.92. Taysha Gene Therapies, Inc. has a fifty-two week low of $1.19 and a fifty-two week high of $4.32. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. The business had revenue of $2.02 million during the quarter, compared to the consensus estimate of $2.05 million. As a group, sell-side analysts expect that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on TSHA shares. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, February 27th. Chardan Capital reaffirmed a “buy” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Wednesday, February 26th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $6.63.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.